This is a StreetInsider.com Premium Only Page

(CNSP) – StreetInsider.com Reports

Feb 2, 2024 05:07 PM CNS Pharmaceuticals (CNSP) Enters Placement Agreement

Jan 30, 2024 05:48 AM CNS Pharmaceuticals (CNSP) Prices 13.33M Share Offering at $0.30/sh

Jan 18, 2024 08:46 AM CNS Pharmaceuticals (CNSP) Appoints Amy Mahery to its Board

Jan 10, 2024 05:31 PM CNS Pharmaceuticals (CNSP) Announces 6.96M Share and Warrant Offering

Dec 18, 2023 08:40 AM CNS Pharmaceuticals (CNSP) Announces Successful Interim Analysis of Efficacy and Safety Data in Study of Berubicin

Nov 22, 2023 09:08 AM CNS Pharmaceuticals (CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Nov 20, 2023 05:29 PM CNS Pharmaceuticals (CNSP) Announces 3.76M Share Offering by Selling Stockholders

Aug 14, 2023 08:39 AM CNS Pharmaceuticals (CNSP) Presents Updated Results from On-Going Study of Berubicin

Aug 3, 2023 08:04 AM CNS Pharmaceuticals (CNSP) Provides Clinical Trial Update for Ongoing Study with Berubicin

May 8, 2023 08:48 AM CNS Pharmaceuticals (CNSP) Appoints Bettina M. Cockroft to its Board

May 3, 2023 08:47 AM CNS Pharmaceuticals (CNSP) Retains Shareholder Intelligence Services to Investigate Potential Naked Short Selling

Apr 14, 2023 11:55 AM CNS Pharmaceuticals (CNSP) Halted on Volatility, Up 150%

Mar 13, 2023 07:05 AM CNS Pharmaceuticals (CNSP) Has No Exposure to Silicon Valley Bank Issues

Mar 9, 2023 09:05 AM CNS Pharmaceuticals (CNSP) Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland

Jan 12, 2023 08:45 AM CNS Pharmaceuticals (CNSP) Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland

Jan 3, 2023 12:01 PM CNS Pharmaceuticals (CNSP) Appoints Faith L. Charles, JD as Chair of the Board of Directors

Dec 8, 2022 09:11 AM CNS Pharmaceuticals (CNSP) Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

Nov 28, 2022 04:53 PM CNS Pharmaceuticals (CNSP) Announces 1-for-30 Reverse Stock Split

Aug 17, 2022 07:19 AM Maxim Group Downgrades CNS Pharmasceuticals Inc. (CNSP) to Hold

Jun 23, 2022 08:35 AM CNS Pharmaceuticals (CNSP) Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Jun 8, 2022 08:35 AM CNS Pharmaceuticals (CNSP) Presents Ongoing Berubicin Clinical Trial Design

Apr 28, 2022 08:36 AM CNS Pharmaceuticals (CNSP) Approved by Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Apr 6, 2022 08:35 AM CNS Pharmaceuticals (CNSP) Approved to Commence Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Apr 5, 2022 08:36 AM CNS Pharmaceuticals (CNSP) Granted Swiss Approval for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Mar 9, 2022 09:20 AM CNS Pharmaceuticals (CNSP) Reiterates Operational Progress and Addresses Recent Share Price Activity

Mar 3, 2022 08:36 AM CNS Pharmaceuticals (CNSP) Reports 2021 Results, Provides Corporate Update

Jan 20, 2022 04:18 PM CNS Pharmaceuticals (CNSP) Announces 24.8M Share Offering by Selling Stockholders

Jan 6, 2022 07:01 AM CNS Pharmaceuticals (CNSP) Announces 12.1M Share Private Placement at $0.95/sh

Dec 2, 2021 08:35 AM CNS Pharmaceuticals (CNSP) Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

Jun 29, 2021 09:27 AM Pre-Open Stock Movers 06/29: (CERE) (CNSP) (VERB) Higher; (DMAC) (CELC) (ALGS) Lower (more...)

Jun 29, 2021 08:36 AM CNS Pharmaceuticals (CNSP) Announces FDA Grants Fast Track Designation to Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

Feb 25, 2021 09:15 AM CNS Pharmaceuticals (CNSP) Berubicin Trial is On Schedule to Commence in March 2021

Feb 2, 2021 08:08 AM Brookline Capital Markets Starts CNS Pharmasceuticals Inc. (CNSP) at Buy

Dec 28, 2020 07:13 AM UPDATE: Ladenburg Thalmann Downgrades CNS Pharmasceuticals Inc. (CNSP) to Neutral

Dec 23, 2020 08:33 AM CNS Pharmaceuticals (CNSP) Announces Pricing of $10 Million Public Offering of Common Stock, Warrants

Dec 17, 2020 09:03 AM CNS Pharmaceuticals (CNSP) Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

Dec 10, 2020 08:39 AM Maxim Group Starts CNS Pharmasceuticals Inc. (CNSP) at Buy, $7 PT

Nov 17, 2020 08:02 AM CNS Pharmaceuticals (CNSP) Announces FDA Filing of IND for its Brain Cancer Drug Berubicin

Nov 9, 2020 08:14 AM CNS Pharmaceuticals (CNSP) Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review

Oct 9, 2020 08:02 AM CNS Pharmaceuticals (CNSP) Begins Manufacturing of Berubicin in Europe

Aug 25, 2020 08:48 AM CNS Pharmaceuticals (CNSP) Provides FDA Update on IND Filing

Aug 24, 2020 06:48 AM Ladenburg Thalmann Starts CNS Pharmasceuticals Inc. (CNSP) at Buy

Aug 20, 2020 08:05 AM CNS Pharmaceuticals (CNSP) Announces Worldwide Clinical Trials as CRO for Phase 2 Berubicin Clinical Trials

Jun 11, 2020 08:03 AM CNS Pharmaceuticals (CNSP) Announces FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

Jun 10, 2020 10:22 AM CNS Pharmaceuticals (CNSP) granted FDA orphan drug designation for Berubicin, for the treatment of malignant glioma

May 18, 2020 08:52 AM CNS Pharmaceuticals (CNSP) trading halt status changed to "additional information requested"

May 11, 2020 08:08 AM CNS Pharmaceuticals (CNSP) announces SEC's suspension of trading is scheduled to terminate at 11:59 p.m. ET on May 15

Mar 12, 2020 04:43 PM CNS Pharmaceuticals (CNSP) Reports Q4 Loss of $0.17/sh

Mar 4, 2020 06:10 AM CNS Pharmaceuticals (CNSP), WPD Pharmaceuticals Inc. Announce Positive FDA Pre-IND Guidance

Jan 13, 2020 08:08 AM CNS Pharmaceuticals (CNSP) Licenses Breakthrough Technology from MD Anderson